Permeability Enhancers Dramatically Increase Zanamivir Absolute Bioavailability in Rats: Implications for an Orally Bioavailable Influenza Treatment

Eric H. Holmes1*, Harikrishna Devalapally2, Libin Li2, Michael L. Perdue3, Gary K. Ostrander1†

1 Department of Cell and Molecular Biology, John A. Burns School of Medicine, Honolulu, Hawaii, United States of America, 2 Absorption Systems, LP, Exton, Pennsylvania, United States of America, 3 FluSolutions Consulting, LLC, Hilo, Hawaii, United States of America

Abstract

We have demonstrated that simple formulations composed of the parent drug in combination with generally regarded as safe (GRAS) permeability enhancers are capable of dramatically increasing the absolute bioavailability of zanamivir. This has the advantage of not requiring modification of the drug structure to promote absorption, thus reducing the regulatory challenges involved in conversion of an inhaled to oral route of administration of an approved drug. Absolute bioavailability increases of up to 24-fold were observed when Capmul MCM L8 (composed of mono- and diglycerides of caprylic/capric acids in glycerol) was mixed with 1.5 mg of zanamivir and administered intraduodenally to rats. Rapid uptake (tmax of 5 min) and a Cmax of over 7200 ng/mL was achieved. Variation of the drug load or amount of enhancer demonstrated a generally linear variation in absorption, indicating an ability to optimize a formulation for a desired outcome such as a targeted Cmax for enzyme saturation. No absorption enhancement was observed when the enhancer was given 2 hr prior to drug administration, indicating, in combination with the observed tmax, that absorption enhancement is temporary. This property is significant and aligns well with therapeutic applications to limit undesirable drug-drug interactions, potentially due to the presence of other poorly absorbed polar drugs. These results suggest that optimal human oral dosage forms of zanamivir should be enteric-coated gelcaps or softgels for intraduodenal release. There continues to be a strong need and market for multiple neuraminidase inhibitors for influenza treatment. Creation of orally available formulations of inhibitor drugs that are currently administered intravenously or by inhalation would provide a significant improvement in treatment of influenza. The very simple GRAS formulation components and anticipated dosage forms would require low manufacturing costs and yield enhanced convenience. These results are being utilized to design prototype dosage forms for initial human pharmacokinetic studies.

Introduction

Seasonal influenza outbreaks generally cause between 3 and 5 million annual cases and lead to 250,000 to 500,000 deaths worldwide [1]. In cases of pandemic influenza, resulting in widespread and sustained transmission of the disease, hundreds of millions can be infected, with a corresponding increase in deaths [2]. Particularly worrisome are the appearances of a novel hemagglutinin subtype to which there is no population immunity or the possibility of initiation of human-to-human transmission from a highly lethal animal flu strain. Vaccination may certainly be an effective means for prevention, however, vaccines are strain-specific, and vaccines formulated for one flu season are often ineffective in subsequent seasons due to the rapid evolution of the virus, giving rise to new circulating strains. Protection with vaccines, while proven, can also have variable effectiveness in different settings and age groups. Alternatively, antiviral drugs such as neuraminidase inhibitors are less sensitive to differing strains and can be used to treat influenza in all age groups by reducing the severity of symptoms and shortening the duration of the illness [3].

Influenza A and B virus particles are composed of multiple proteins encasing approximately seven or eight pieces of negative sense viral RNA [4]. The two major virus particle surface glycoproteins are hemagglutinin and neuraminidase (3). Hemagglutinin has lectin activity and binds to terminal α2→6 and/or α2→3 sialic acid residues on N- and O-linked surface proteins of the host cell, mediating cell infection and accumulation of replicated viruses. Neuraminidase subsequently cleaves these sialic acid residues, allowing release of replicated virus from the host cell. Failure of neuraminidase cleavage of the newly replicated virus
particles prevent their release and stops subsequent host cell infection and ultimately further viral replication [3,4].

Studies demonstrate that the substrate binding pocket of influenza virus neuraminidase is conserved among strains, and its X-ray structure has been determined [5]. Based on this information, rational drug design has given rise to a class of viral neuraminidase-specific inhibitors that have been shown to bind with high affinity and have therapeutic utility in treatment of influenza [6–8]. Consequently, inhibition of viral neuraminidase has become a major therapeutic approach in the treatment of influenza, with several approved drugs including the neuraminidase-specific inhibitors oseltamivir, zanamivir, peramivir and laninamivir. Of these inhibitors, two have been approved by the Food & Drug Administration (FDA) for treatment of influenza, Tamiflu® (oseltamivir), marketed by Roche, which is orally delivered, and Relenza® (zanamivir), marketed by GlaxoSmithKline (GSK), which is inhaled. In Japan, two additional drugs, Rapiacta® (peramivir-IV) and Inavir® (laninamivir-inhaled), are approved.

Inhibitors such as oseltamivir carboxylate, zanamivir, and peramivir were developed through structure-based drug design and are generally transition-state analogs of sialic acid having high affinity and specificity for multiple subtypes of viral neuraminidase [9–13]. These inhibitors are generally 5- to 6-member ring structures with multiple side chains, the most significant being a carboxylic acid group and a basic group in the form of either a primary amine or a guanidino group. These compounds are highly polar, not metabolized in vivo, and, although they are effective viral neuraminidase inhibitors, the high polarity and lack of transporter protein binding generally results in under 2% oral bioavailability [3,14]. In such instances, administration routes such as inhalation or intravenous have either been used or are proposed. Other approaches are also being explored to enhance permeability and more conveniently administer these drugs (e.g., via oral dosing). Owing to recent circulation of influenza strains that have become resistant to oseltamivir, it is generally agreed that oral availability of an alternative neuraminidase inhibitor would provide a useful tool in the influenza antivirals arsenal. This can include multi-binding-site inhibitors computationally designed to target simultaneously several adjacent binding sites of such strains as H5N1 or the oseltamivir-resistant H274Y variant [15]. Interestingly, those compounds determined to have the most favorable ligand efficiency index for multi-site binding to neuraminidase are also highly polar and contain guanidino groups suggesting poor oral bioavailability and potential suitability for the approach described herein [15].

One exception to the otherwise low oral bioavailability of viral neuraminidase inhibitors has been achieved with a prodrug wherein the carboxyl group of oseltamivir carboxylate has been modified to form an ethyl ester, thus reducing the polarity of the molecule. The oral bioavailability of oseltamivir has been reported to be at least 35% in contrast to the 2% oral bioavailability of its oseltamivir carboxylate precursor [16,17]. Analogous modifications of either zanamivir or peramivir have not improved oral bioavailability, as the much higher polarity of their guanidino group compared to the primary amine of oseltamivir still prevents substantial oral absorption. As a result, to date, neuraminidase inhibitors that contain a guanidino group (such as zanamivir and peramivir) have been resistant to efficacious oral formulation development. A new prodrug strategy has been employed by Amidon’s group [18] using amino acid derivatives of zanamivir to target the intestinal membrane transporter hPepT1 to increase drug absorption via an active transport mechanism [19]. Another recent approach employs a longer hydrophobic chain heptyl ester derivative of zanamivir with ion-pairing by 1-hydroxy-2-naphthoic acid to enhance the lipophilicity and promote permeability [20]. Increased zanamivir absorption has been observed with these alternative compositions but their pursuit as development targets is complicated by regulatory requirements that would require a New Drug Application (NDA) and a full drug development program. Alternatives that can enhance absorption of the existing, unmodified approved drug, zanamivir, would have a much shorter regulatory pathway. Our results demonstrate that simple formulations composed of zanamivir in combination with generally recognized as safe (GRAS) permeability enhancers offer an ability to dramatically increase intestinal absorption and a potentially convenient route to an orally available dosage form of a variety of polar neuraminidase inhibitors.

Materials and Methods

Materials

Zanamivir was obtained from Beijing APIfocus Co., Beijing, China. Capmul MCM L8 was obtained from Abitec Corporation, Janesville, WI. Glycerol was obtained from Fisher Scientific, Fair Lawn, NJ. All other reagents were of the highest purity commercially available.

Methods

Ethics Statement. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institutional Animal Care and Use Committee of Absorption Systems, LP (Assurance Number: A4653-01). All efforts were made to minimize suffering and discomfort during the course of the study.

Caco-2 Cell Culture. Caco-2 cells were obtained from American Type Culture Collection (Rockville, MD). Stock cultures were maintained in flasks with DMEM medium supplemented with 10% FBS, 1% non-essential amino acids, 1 mmol/L sodium pyruvate, 100 IU/mL penicillin, and 100 μg/mL streptomycin in a humidified incubator (37°C, 5% CO2). Cells were harvested by trypsinization and seeded at 60,000 cells/cm2 onto Costar Transwell®-12-well dual-chamber plates with collagen-coated, microporous polycarbonate membranes (1.13 cm2 insert area, 0.4 μm pore size; Corning Life Sciences, Acton, MA) for permeability studies. The culture medium was changed three times per week.

Certification of Cells for the Study. Caco-2 cell monolayers that had grown for at least 20 days were subjected to batch quality control testing in which permeation rates were measured for atenolol, digoxin, estrone-3-sulfate, lucifer yellow (LY), and prropanolol. In addition, the transepithelial electrical resistance (TEER) across each experimental monolayer was tested prior to an experiment.

Tolerability Assessment of Excipients in Caco-2 Cell Monolayers. Tolerability was assessed with zanamivir (15 μg/mL) in the presence and absence of the two excipients (each at 5%) in Caco-2 cell monolayers, based on the rate of permeation of the fluorescent monolayer integrity marker LY immediately post-exposure and after 4 hr recovery.

Unidirectional Permeability of Zanamivir across Caco-2 Cell Monolayers in the Presence and Absence of Excipients. Unidirectional (A-to-B) permeability of zanamivir was determined at 15 μg/mL in the absence and presence of varying concentrations of excipients in Caco-2 cell monolayers. The assay buffer was Hanks’ balanced salt solution (HBSS) supplemented with 10 mM 4-(2-hydroxyethyl)-1-piperazineetha-
Results

Impact of permeability enhancers on the transport of neuraminidase inhibitors across Caco-2 cell monolayers

Initial screening experiments testing transport of the neuraminidase inhibitor peramivir across Caco-2 cell monolayers, utilizing over 20 potential permeability enhancer compounds or compositions, demonstrated a broad range of impact on drug permeability (results not shown). Two enhancers, glycerol and Capmul MCM L8, provided substantially increased drug transport across Caco-2 cell monolayers and were selected for a more extensive evaluation with an alternate neuraminidase inhibitor, zanamivir, the active ingredient in the drug Relenza® (GlaxoSmithKline, Boston, MA, USA).

Figure 1 shows results of Caco-2 cell assays with zanamivir utilizing optimized concentrations of both Capmul MCM L8 and glycerol. Optimized concentrations of each were derived based upon conditions found to provide the highest permeability and no impact on Caco-2 cell viability and membrane integrity (viability and tolerability test results not shown). Under the optimized conditions, both Capmul MCM L8 and glycerol provided over a 5-fold increase in the apparent permeability coefficient \( P_{app} \) of zanamivir. Capmul MCM L8 was an inherently more potent permeability enhancer with zanamivir, as a similar increase in zanamivir transport across the membrane was observed at a 20-fold lower concentration than with glycerol. These results demonstrated a clear ability for permeability enhancers to increase the transport of zanamivir across a biological barrier (a monolayer of intestinal epithelial cells); therefore, the study was expanded to explore the potential of these enhancers for increased intestinal absorption in a rat model system.
Impact of permeability enhancers on zanamivir absolute bioavailability in rats

Results from Caco-2 cell monolayer permeability studies suggested the permeability enhancers glycerol and Capmul MCM L8 could provide a significant increase in zanamivir absorption despite its high polarity and inherently low oral absolute bioavailability of under 2% [3,14]. Experiments to test the ability of permeability enhancers to increase the absolute bioavailability of polar neuraminidase inhibitors containing guanidino groups indicated there was no absorption enhancement effect when delivered orally directly into the stomach (results not shown), presumably due to dilution of the enhancer. As a result, the experiments presented were designed using intraduodenal administration of the drug/enhancer formulation in an effort to mimic the performance of an enteric coated dosage form to be released in the duodenum.

Figure 2 depicts results from studies using intraduodenal administration of zanamivir/enhancer formulations in male Sprague-Dawley rats. In these experiments, rats fitted with a cannula in the duodenum were administered 1.5 mg of zanamivir in 50 μL vehicles composed of either PBS, glycerol, or Capmul MCM L8. The results demonstrate low absorption of zanamivir in the absence of enhancer, along with dramatically increased absolute bioavailability in their presence. The absolute bioavailability of zanamivir was increased 4.7- and 23.7-fold in 50 μL of

Table 1. Summary of Pharmacokinetic Parameters for Zanamivir from Different Formulations after Intraduodenal Administration in Male Sprague-Dawley Rats at 1.5 mg/animal.

| PK Parameter        | PBS    | Glycerol | Capmul MCM L8 @ -2 hr | PBS (Glycerol @ -2 hr) | PBS (Capmul MCM L8 @ -2 hr) |
|---------------------|--------|----------|------------------------|------------------------|-----------------------------|
| Cmax (ng/mL)        | 134    | 948      | 7233                   | 77.4                   | 48.6                        |
| tmax (hr)           | 0.5    | 0.5      | 0.08                   | 0.58                   | 1                           |
| t1/2 (hr)           | 0.83   | 0.29     | 0.49                   | 1.24                   | 0.86                        |
| AUClast (hr·ng/mL)  | 162    | 754      | 3803                   | 112                    | 66.1                        |
| AUCc (hr·ng/mL)     | 244    | 781      | 4005                   | 156                    | 69.8                        |
| Dose-normalized Values1 |
| AUClast (hr·kg·ng/mL/mg) | 30.6  | 145      | 715                    | 21.1                   | 12.7                        |
| AUCc (hr·kg·ng/mL/mg) | 46.6  | 153      | 753                    | 29.1                   | 13                          |
| Bioavailability (%) | 1.59   | 7.53     | 37.7                   | 1.1                    | 0.66                        |

Cmax: Maximum plasma concentration; tmax: Time to maximum plasma concentration; t1/2: half-life; AUClast: Area Under the Curve, calculated to the last observable time point; AUCc: Area Under the Curve, extrapolated to infinity;

1Dose normalized by dividing the parameter by the nominal dose of 1.5 mg/animal.

doi:10.1371/journal.pone.0061853.t001
glycerol and Capmul MCM L8, respectively, compared to PBS. In Table 1, the pharmacokinetic parameters for zanamivir using the indicated formulations are presented. Most notably, a Cmax of over 7000 ng/mL was achieved when Capmul MCM L8 was used as the enhancer. Figure 3 depicts the plasma zanamivir concentrations over time. These results demonstrate a rapid intraduodenal uptake of the drug and its clearance.

As an initial test of the duration of the permeability enhancement effect of glycerol and Capmul MCM L8, experiments were conducted in which the permeability enhancers were administered 2 hr prior to zanamivir dosing (see Figure 2A and 2B). In these experiments, temporal separation of the enhancer and drug by 2 hr resulted in no enhanced absorption; for both enhancers, the absolute bioavailability was equivalent to that of the negative control. Clearly, the enhancement effect is transient and lasts well under 2 hr.

Variation of intraduodenal enhancer and zanamivir levels on absolute bioavailability

The effect of increasing intraduodenally administered Capmul MCM L8 at a fixed 1.5 mg zanamivir drug load on absolute bioavailability is shown in Figure 4. A roughly linear increase in both absolute bioavailability of zanamivir and Cmax are observed as Capmul MCM L8 amounts are increased 3-fold from 25 µL to 75 µL. These results demonstrate that enhancer amounts can be varied to optimize drug absorption and the associated pharmacokinetic parameters.

Figure 5 summarizes the reciprocal results from varying zanamivir levels at a fixed 50 µL amount of Capmul MCM L8 after intraduodenal administration. Although there was only a modest difference in the absolute bioavailability of zanamivir as the dose varied 4-fold from 0.75 mg to 3.0 mg, there was a substantial impact on the resulting Cmax. The Cmax varied roughly proportionately to the drug load, with a short tmax of 0.08, 0.08, and 0.14 hr for the 0.75 mg, 1.5 mg, and 3.0 mg zanamivir dosages, respectively. These results suggest that once the enhancer opened tight junctions to facilitate paracellular absorption, very rapid drug uptake occurred for a short duration, presumably due to only transient stimulation of the paracellular pathway.

Discussion

Viral neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, peramivir) bind to influenza virus neuraminidase with high specificity and affinity and have been used therapeutically for the treatment of acute influenza [3]. In contrast to influenza vaccines,
neuraminidase inhibitors are not intended to prevent influenza infection, but have the advantage of lacking much of the strain specificity of vaccines, thereby providing more generalized utility in treatment to lessen the symptoms and shorten their duration. The broad utility of neuraminidase inhibitors among influenza virus strains is associated with the conserved sequence within the neuraminidase active site [5]. However, associated with the therapeutic use of neuraminidase inhibitors, in particular Tamiflu®, (oselatamivir), has been the appearance of resistant strains, which lessens the value of a single therapeutic compound. For example, 2009 tests of seasonal H1N1 and pandemic flu strains were 99.6% and 0.5% resistant to Tamiflu®, respectively [21]. In contrast, zanamivir resistance has not been observed [21] and the reported Tamiflu® resistant flu strains remain zanamivir sensitive. Thus, at present and until resistant strains to other neuraminidase inhibitors appear and limit their utility, zanamivir and other neuraminidase inhibitor compounds become important alternate drugs for influenza treatment.

Neuraminidase inhibitors were obtained through rational drug design as transition state analogs to achieve high enzyme specificity and affinity. Therapeutic effects are caused by saturating the enzyme with inhibitor and reliance on their high affinity and slow off-rate of binding to provide a sustained impact on viral replication between dosing intervals [3]. For oral or intravenous formulations, this involves achievement of a high Cmax capable of saturating the enzyme consistent with Michaelis-Menten enzyme kinetics. In the case of inhaled formulations, high local concentrations of inhibitor are achieved at the surface of infected cells, resulting in the same high level of inhibitor binding to the enzyme.

Inherent to their molecular design is the presence of key polar functional groups, including a negatively charged carboxylic acid group and a positively charged primary amine or guanidino group. These functional groups give rise to the overall high polarity of this class of drugs, and their failure to be recognized by active transporter proteins renders them Biopharmaceutical Classification System (BCS) class 3 drugs (high solubility, low permeability). As a result, drug delivery is a challenge.

Efforts to address high polarity with a resulting increase in intestinal permeability were successful in the case of oselamivir carboxylate, which contains both a carboxyl group and a primary amine [17]. The absolute bioavailability of oselamivir carboxylate was increased from under 5% to 35% or greater by blocking the carboxylic acid group with an ethyl ester. Once absorbed, esterases cleave the ester linkage, yielding the active oselamivir carboxylate drug form. In contrast, a simple ethyl ester prodrug approach was not capable of enhancing the intestinal absorption of a variant of oselamivir carboxylate, GS4116 carboxylate, containing instead the much more basic guanidino group. GS4116 carboxylate is a 10-fold more potent inhibitor than oselamivir carboxylate, with oral bioavailability under 5% [16]. The GL4116 ethyl ester derivative, despite being somewhat less polar, retains a bioavailability of under 5%. Thus, despite the 10-fold increased potency of the guanidino-containing variant, bioavailability limitations were a major driver in the design of the marketed product. The simple ester modification of oselamivir carboxylate, creating a prodrug structure, has allowed Tamiflu® to be delivered orally. This convenient dosing route has allowed Tamiflu® to dominate the market. The pattern of very poor oral bioavailability among neuraminidase inhibitors containing a guanidino group (zanamivir, lanaminivir, and peramivir) is consistent. Each has oral bioavailability under about 2%. This has required the use of alternative drug delivery strategies such as inhalation or intravenous formulations [3,14].

Taken together, the results of this study demonstrate enhanced absorption of the very polar neuraminidase inhibitor zanamivir when delivered intraduodenally in rats. Significantly increased absolute bioavailability at a high Cmax was observed with some variation in the degree of absolute bioavailability increase observed between experiments due to common variability between animals and experiments. The results demonstrated that variation of both enhancer and drug amounts in a formulation can be used to achieve a desired absolute bioavailability and Cmax for optimization of human formulations for oral zanamivir administration. The short tmax and transient stimulation of the paracellular pathway associated with zanamivir absorption suggests that oral formulations for human use in influenza treatment should be in enterico-coated dosage forms to allow rapid release in the duodenum at relatively high enhancer and zanamivir local concentrations. The results presented provide a strong basis for their extension into the creation of an oral zanamivir formulation for influenza treatment.

Conclusions

The results presented demonstrate that absorption enhancers, when present in high concentration in the duodenum, give rise to a dramatic increase in the absolute bioavailability and high Cmax of very polar neuraminidase inhibitors. This provides a new and simple potential formulation alternative for the oral administration of polar neuraminidase inhibitors comprising drug and absorption enhancer in an enteric coated dosage form for influenza treatment in humans.

Acknowledgments

The expert assistance of Li-Jen Huang, Feng Zhou, James Merdink, Justin Wright, Jessica Helwig, and Joseph Rager, all from Absorption Systems, LP, is gratefully acknowledged.

Author Contributions

Conceived and designed the experiments: EHH HD LL MLP GKO. Performed the experiments: EHH HD LL MLP GKO. Analyzed the data: EHH HD LL MLP GKO. Contributed reagents/materials/analysis tools: EHH HD LL MLP GKO. Wrote the paper: EHH HD LL MLP GKO.

References

1. World Health Organization (2009) World Health Organization Fact Sheet 211. April 2009
2. Nicholls H (2006) Pandemic Influenza: The Inside Story. PLoS Biology 4: e50.
3. Moscona A (2005) Neuraminidase inhibitors for influenza. N Engl J Med 353: 1363–1373.
4. Garman E, Laver WG (2005) The structure, function, and inhibition of influenza virus neuraminidase. In: Viral Membrane Proteins: Structure, Function, and Drug Design. Wolfgang Fischer (ed). Kluwer Academic/Plenum Publishers, New York.
5. Coleman PM (1994) Influenza viral neuraminidase: structure, antibodies, and inhibitors. Protein Science 3: 1667–1686.
6. Vaghee JN, Smith PW, Sollsis SL, Block TJ, Saharabudde A, et al. (1998) Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 6: 735–746.
7. Kim CU, Lew W, Williams MA, Liu H, Zhang L, et al. (1997) Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carboxylic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119: 601–609.
8. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Pin YP, et al. (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443: 445–49.
9. Babu YS, Chand P, Bantia S, Kotian P, Delughani A, et al. (2000) BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 43: 3482–6.

10. Sudbeck EA, Jedrzejas MJ, Singh S, Brouillette WJ, Air GM, et al. (1997) Guanidinobenzoic acid inhibitors of influenza virus neuraminidase. J Mol Biol 267: 584–94.

11. Chand P, Babu YS, Bantia S, Chu N, Cole LB, et al. (1997) Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design. J Med Chem 40: 4030–52.

12. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, et al. (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363: 418–23.

13. Aoki FY, Hayden FG (1999) Zanamivir. A potent and selective inhibitor of influenza A and B viruses. Clin Pharmacokinet 36 Suppl 1: v–ix.

14. Cass LM, Efthymiopoulos C, Bye A (1999) Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 36 Suppl 1: 1–11.

15. Garcia-Sosa AT, Stid S, Maran U (2008) Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant. J Chem Inf Model 48: 2074–2080.

16. Li W, Escarpe PA, Eisenberg EJ, Candy KC, Sweet C, et al. (1998) Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 42: 647–53.

17. Mendel DB, Tai CY, Escarpe PA, Li W, Siebwill RW, et al. (1996) Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 42: 640–6.

18. Miller JM, Dahan A, Gupta D, Varghese S, Amidon GL (2010) Enhancing the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir. Mol Pharm 7: 1223–34.

19. Gupta SV, Gupta D, Sun J, Dahan A, Tsume Y, et al. (2011) Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach. Mol Pharm. 8: 2338–67.

20. Liu KC, Lee PS, Wang SY, Cheng YS, Fang JM, et al. (2011) Intramolecular ion-pair prodrugs of zanamivir and guanidine-oseltamivir. Bioorg Med Chem 19: 4796–802.

21. 2008–2009 Influenza Season Week 32 ending August 15, 2009. Flu Activity & Surveillance. Centers for Disease Control and Prevention (CDC). August 21, 2009. Available: http://www.cdc.gov/flu/weekly/weeklyarchives2008-2009/weekly32.htm